Direct answer
Direct answer: Valuing Tenet Healthcare requires treating it as two separate businesses combined at the enterprise level, then subtracting net debt to arrive at equity value. The Ambulatory Care segment through USPI earns a 39.0% adjusted EBITDA margin and deserves a higher EBITDA multiple than the Hospital Operations segment, which earns an 18.0% margin. With full-year 2026 adjusted EBITDA guidance of $4.83 to $5.03 billion and adjusted free-cash-flow guidance of $2.725 to $3.025 billion, the most important questions are: what sustainable EBITDA multiple does each segment deserve, how durable is the current margin profile, and how quickly does free-cash-flow conversion reduce the leverage that currently separates enterprise value from equity value.
How to think about Tenet's valuation
This page does not declare Tenet Healthcare cheap or expensive. Valuation depends on the current market price, which changes continuously, and on assumptions about future earnings, growth, and risk that each investor must form independently. Instead, this page provides the analytical framework for building a valuation, based on the company's structure and Q2 2026 financial results.
For hospital and healthcare-services companies, EV/EBITDA is the most commonly used primary valuation metric for three reasons. First, hospital companies often carry significant depreciation and amortization from large property, plant and equipment balances and from acquisitions, making EBITDA a cleaner measure of operating cash generation than net income. Second, most hospital company debt agreements use EBITDA-based covenants, so the market pays close attention to this metric. Third, EBITDA-based valuation is capital-structure neutral, which is important for companies like Tenet that regularly adjust their leverage through debt paydown, refinancing, and share repurchases.
The limitation of EV/EBITDA alone is that it does not account for capex intensity, working capital requirements, interest costs, or taxes. Free-cash-flow yield, defined as free cash flow divided by equity market capitalization (or enterprise free cash flow yield defined against enterprise value), provides the reality check on whether the EBITDA being valued actually converts to distributable cash. Tenet's guidance for $2.725 to $3.025 billion in full-year 2026 adjusted free cash flow provides a strong conversion ratio from its $4.93 billion EBITDA guidance midpoint, suggesting the business is not consuming most of its operating earnings in maintenance capital or working capital.
Sum-of-the-parts framework
The most analytically rigorous approach to Tenet's valuation is a sum-of-the-parts model that values each segment separately and then subtracts net debt to derive equity value. The logic is straightforward: two businesses with different growth rates, margins, competitive dynamics, and risk profiles should not trade at the same blended multiple. Applying a single blended multiple to consolidated EBITDA either overvalues the lower-quality segment or undervalues the higher-quality one.
| Segment | Q2 2026 Adjusted EBITDA (annualized) | Adjusted EBITDA margin | Illustrative multiple range |
|---|---|---|---|
| Ambulatory Care (USPI) | ~$2.168 billion (4x $542M) | 39.0% | 12x to 18x (high-quality ASC platform) |
| Hospital Operations | ~$3.048 billion (4x $762M) | 18.0% | 7x to 10x (for-profit hospital operator) |
| Consolidated (2026 guidance midpoint) | $4.93 billion | 23.2% | Blended result of segment analysis |
The multiples shown in the table above are illustrative ranges based on historical trading ranges for comparable businesses and are provided for educational purposes only. Actual market multiples at any given time depend on interest rates, growth expectations, competitive dynamics, regulatory environment, and investor sentiment. They are not a prediction of what multiple Tenet will or should trade at.
The key insight from a sum-of-the-parts analysis is that the Ambulatory segment, despite representing approximately 28% of consolidated revenue, may represent 40 to 50% or more of the implied enterprise value at the segment-level multiples appropriate for an ASC platform. This is why the investment community cares intensely about USPI's growth and margin trajectory relative to the hospital business.
After computing segment enterprise values and summing them, the investor subtracts net debt (total debt minus cash) to arrive at the implied equity value, then divides by the diluted share count to arrive at an implied value per share for comparison with the current market price.
Key valuation metrics to watch
The following metrics are the most useful for monitoring Tenet's valuation relative to both its own history and its peers.
| Metric | Why it matters for valuation |
|---|---|
| EV / forward adjusted EBITDA | The primary valuation benchmark for healthcare services; should be computed separately for each segment where possible |
| Free-cash-flow yield (equity) | Free cash flow per share divided by stock price; provides a direct return estimate and a check on EBITDA conversion |
| Net debt / adjusted EBITDA | Leverage ratio; declining leverage expands the equity value implied by a given enterprise value |
| Price / adjusted EPS | Traditional earnings multiple; affected by buybacks as well as operating performance, so compare growth in total EBITDA and per-share EBITDA side by side |
| Ambulatory EBITDA as % of total EBITDA | Mix shift toward the higher-quality segment is a positive valuation catalyst if the market assigns different multiples to each segment |
| Free-cash-flow conversion rate | Adjusted free cash flow divided by adjusted EBITDA; shows how much of operating earnings reaches investors after capex, interest, and taxes |
The Q2 2026 full-year guidance midpoints imply a free-cash-flow conversion rate of approximately 58% ($2.875 billion adjusted free cash flow divided by $4.93 billion adjusted EBITDA). This is a meaningful conversion rate for a capital-intensive healthcare company that must maintain hospital facilities and fund USPI growth simultaneously. Investors should track whether this conversion rate is sustainable or reflects favorable timing of capital expenditure and working capital in the guidance period.
Scenario analysis
A robust valuation does not rest on a single set of assumptions. The following scenarios illustrate how the equity value estimate would differ based on reasonable variations in the key drivers. These are illustrative examples for educational purposes, not buy or sell recommendations.
Bull scenario
Adjusted EBITDA reaches the high end of guidance ($5.03 billion) and continues growing 10 to 12% annually for several years. The Ambulatory Care segment's EBITDA grows faster than Hospital Operations, shifting the mix toward the higher-multiple business. Free-cash-flow conversion remains near 58%. Buybacks reduce the share count by 5% per year. Under these assumptions, per-share free cash flow compounds rapidly and the equity multiple expands as leverage declines and the business quality mix improves.
Base scenario
Adjusted EBITDA reaches the midpoint of guidance ($4.93 billion) and grows 8 to 10% annually. Both segments contribute roughly proportionally. Free-cash-flow conversion is stable near 55 to 58%. Buybacks reduce the share count by 3 to 4% per year. This scenario produces solid earnings per share growth driven by a combination of operational improvement and capital return.
Bear scenario
Adjusted EBITDA falls short of guidance as supplemental payments moderate and payer mix weakens. Full-year adjusted EBITDA comes in at $4.50 to $4.70 billion instead of the guided range. Free-cash-flow conversion falls to 50% or below as labor and supply-cost pressures return. The share repurchase program slows to conserve cash. In this environment, the EV/EBITDA multiple applied by the market may also contract as investors become more cautious about the durability of the margin improvement, compressing equity value further than the earnings decline alone would suggest.
The scenario analysis reveals why THC carries higher implied stock volatility than a lower-leverage healthcare company. At significant leverage, the equity value is sensitive both to changes in EBITDA and to changes in the enterprise value multiple. A combination of lower EBITDA and multiple contraction compresses equity value nonlinearly compared with the EBITDA decline alone.
Frequently asked questions
What valuation metric is most useful for Tenet Healthcare?
EV/EBITDA is the most widely used valuation metric for hospital and healthcare-services companies because it is capital-structure neutral and accounts for the EBITDA-based covenants common in healthcare company debt agreements. For Tenet, analysts typically value the two segments separately using different EBITDA multiples, reflecting the higher quality and growth profile of the Ambulatory Care segment through USPI. Free-cash-flow yield is the second most important metric, because the ultimate test of any EBITDA figure is how much of it converts to cash after maintenance capital, working capital, interest, and taxes.
What is a sum-of-the-parts valuation for Tenet Healthcare?
A sum-of-the-parts framework values Tenet's two segments separately, then subtracts net debt to arrive at equity value. The Ambulatory Care segment, with higher growth and a 39% adjusted EBITDA margin, typically commands a higher EV/EBITDA multiple than the hospital business. Hospital operators in the U.S. have historically traded at 7 to 10 times EBITDA, while high-quality ambulatory surgery platforms have traded at 12 to 18 times EBITDA. Applying different multiples to the Q2 2026 annualized segment EBITDA figures and subtracting net debt provides a range of equity value estimates that can be compared to the current market price.
Why does Tenet's stock trade with high volatility?
Tenet's stock has historically been more volatile than healthcare staples peers because the company carries significant leverage, because a meaningful proportion of hospital revenue depends on supplemental government payments that can change year to year, because payer mix is sensitive to economic conditions, and because the stock tends to attract investors who model the leverage and free-cash-flow generation aggressively. At high leverage, a given change in EBITDA produces a larger percentage change in equity value, amplifying stock-price movements relative to earnings changes.
How should investors think about Tenet's leverage in valuation?
Healthcare companies typically carry long-term debt, and Tenet is no exception. Leverage matters in valuation because it creates a wedge between enterprise value and equity value: the higher the net debt, the more EBITDA growth is required to generate equity appreciation. Investors should track the net debt to adjusted EBITDA ratio over time. A declining ratio, driven by strong free-cash-flow conversion, reduces refinancing risk and increases the proportion of future EBITDA growth that accrues to equity holders. The full-year 2026 adjusted free-cash-flow guidance of $2.725 to $3.025 billion implies meaningful annual deleveraging capacity.